Haynes W, Davenport A, Webb D. Endothelin: progress in pharmacology and physiology. Trends Pharmacol Sci. 1993;14:225-8 pubmed

Adachi M, Yang Y, Trzeciak A, Furuichi Y, Miyamoto C. Identification of a domain of ETA receptor required for ligand binding. FEBS Lett. 1992;311:179-83 pubmed

Eguchi S, Hirata Y, Ihara M, Yano M, Marumo F. A novel ETA antagonist (BQ-123) inhibits endothelin-1-induced phosphoinositide breakdown and DNA synthesis in rat vascular smooth muscle cells. FEBS Lett. 1992;302:243-6 pubmed

Ishikawa K, Fukami T, Nagase T, Fujita K, Hayama T, Niiyama K, et al. Cyclic pentapeptide endothelin antagonists with high ETA selectivity. Potency- and solubility-enhancing modifications. J Med Chem. 1992;35:2139-42 pubmed

Ihara M, Noguchi K, Saeki T, Fukuroda T, Tsuchida S, Kimura S, et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 1992;50:247-55 pubmed

Atkinson R, Pelton J. Conformational study of cyclo[D-Trp-D-Asp-Pro-D-Val-Leu], an endothelin-A receptor-selective antagonist. FEBS Lett. 1992;296:1-6 pubmed